trial

Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode psychosis-a Pilot Study

NCTId NCT00511277
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 60 (estimated)
Sponsored by Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Primary completion 2010-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2007-08
Primary completion
2010-10
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Quetiapine

Sponsors

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbHLead Sponsor
University of GöttingenCollaborator

Investigators

4
Peter G. Falkai, Prof. Dr.Study Director
Thomas Wobrock, MD PhDPrincipal Investigator
Andreas Heinz, MD PhDPrincipal Investigator
Georg Juckel, MD PhDPrincipal Investigator

Sites

1 total
Göttingen, Germany

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE4
Primary Completion Date
2010-10
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
lead_sponsor
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
company
collaborator
University of Göttingen
company
indication
Schizophrenia
indication
Depression
indication
Schizophrenia
indication
investigator
Peter G. Falkai, Prof. Dr.
person
Thomas Wobrock, MD PhD
person
Andreas Heinz, MD PhD
person
Georg Juckel, MD PhD
person